EWA
SUPN icon

Exit Wealth Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Exit Wealth Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,651
Closed -$430K – 156
2025
Q4 		$430K Buy
+8,651
New +$421K 0.25% 83

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Exit Wealth Advisors's SUPN Position: Q1 2026 in Review

Exit Wealth Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 8,651 shares — an estimated $430K sold.

Exit Wealth Advisors first reported a position in SUPN in Q4 2025 and held it in 1 quarter. The position peaked at $430K in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Exit Wealth Advisors reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Exit Wealth Advisors sold 8,651 Supernus Pharmaceuticals shares in Q1 2026, an estimated $430K.
  • Exit Wealth Advisors first reported a position in Supernus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Exit Wealth Advisors's Supernus Pharmaceuticals position peaked at $430K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Exit Wealth Advisors's 13F filing for Q1 2026, filed 11 May 2026.